DONATE
DONATE →

Clinical trial 2026-526251-60-00 · Unresectable stage III non-small cell lung cancer

Strongers editorial cover for clinical study 2026-526251-60-00 (Phase II), status: authorised — Unresectable stage III non-small cell lung cance.
Oncology research 07 Sep 2026

Clinical trial 2026-526251-60-00 (phase II) is «authorised» on CTIS (EU Clinical Trials Information System).

Condition: Unresectable stage III non-small cell lung cancer · Registered interventions: IMFINZI 50 mg/mL concentrate for solution for infusion · Recorded dates (source): 2026-08-31.

Source: https://euclinicaltrials.eu/ctis-public/view/2026-526251-60-00

A newsletter for those who compete, those who donate, those who believe in research

Events, awarded grants, stories of the people who make research possible. One email a month, no spam.